Here are the S-3 shelf registrations from GlucoTrack Inc New (GCTK) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow GCTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GCTK filings page.
Glucotrack, Inc. is registering 3,224,803 shares of common stock for resale by warrant holders from a December 2025 private placement. The shares consist of 1,033,591 shares underlying pre-funded warrants with a $0.001 exercise price, 2,067,182 shares underlying common warrants with a $3.87 exercise price, and 124,030 shares underlying placement agent warrants with a $4.257 exercise price. Glucotrack will not sell shares or receive proceeds from these resales.
The registered shares equal about 354% of the 910,688 shares outstanding as of January 12, 2026, creating significant potential dilution and stock overhang. The company is a smaller reporting company developing a fully implantable continuous blood glucose monitor and has reported promising first-in-human accuracy data but also substantial historical losses, going concern doubts, and a history of Nasdaq listing compliance issues.